Renovorx Inc   (RNXT)
Other Ticker:  
Price: $1.7800 $0.06 3.488%
Day's High: $1.7955 Week Perf: 29.93 %
Day's Low: $ 1.62 30 Day Perf: 18.67 %
Volume (M): 33 52 Wk High: $ 5.75
Volume (M$): $ 58 52 Wk Avg: $1.83
Open: $1.67 52 Wk Low: $0.53

 Market Capitalization (Millions $) 19
 Shares Outstanding (Millions) 11
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -9
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Renovorx Inc
Renovorx Inc is a medical technology company that develops innovative solutions for the treatment of cardiovascular diseases. The company specializes in developing catheter-based therapies, such as drug-coated balloons and stents, to address various cardiovascular conditions, including peripheral artery disease and coronary artery disease. Renovorx Inc aims to improve patient outcomes by providing minimally invasive and effective treatment options. Through its cutting-edge technologies, the company strives to revolutionize the field of cardiovascular interventions and enhance the quality of life for patients.

   Company Address: 4546 El Camino Real Los Altos 94022 CA
   Company Phone Number: 284-4433   Stock Exchange / Ticker: NASDAQ RNXT
   RNXT is expected to report next financial results on March 30, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Renovorx Inc

Renovorx Inc Witnesses Decline in Q3 2023 Financial Performance, Sets Path for Recovery

As the earnings season progresses, financial results of various companies are being unveiled. One notable player in the Major Pharmaceutical Preparations sector, Renovorx Inc, recently disclosed its operating loss for the most recent fiscal period ending September 30, 2023. While the figures may seem concerning at first glance, a closer look reveals some interesting developments that could shape the company's future trajectory.
Operating Loss Reduction:
Renovorx Inc reported an operating loss of $-2.983 million for the third quarter of 2023. However, comparing this figure with the same period in 2022, we see a positive trend. In the third quarter of 2022, the operating loss was $-2.161 million, indicating a reduction in losses year-over-year. This demonstrates the company's efforts to streamline operations and improve efficiency, which is essential for its long-term viability.

Renovorx Inc

Renovorx Inc's Working Expenditures Surge in Q2 2023, Deficit Widens to $-3.375 Million, Analysts Await Revenue Boost

Renovorx Inc, a company operating in the Major Pharmaceutical Preparations industry, recently released its financial results for the fiscal second quarter of 2023. The company reported an operating deficit of $-3.375 million, which is a significant worsen from the $-2.614 million deficit in the same quarter of the previous year.
Analysts are now speculating whether Renovorx Inc may start reporting revenue soon, which could potentially alleviate the deficit. Additionally, it is worth noting that the company has experienced a decrease in diminishing returns compared to the same period last year. In the second quarter of 2023, the shortfall was $-2.327 million, while it was $-2.594 million in the second quarter of 2022.

Renovorx Inc

Renovorx Inc's Groundbreaking Therapies Make Strides in Cancer Treatment Development

Renovorx Inc is a clinical-stage biopharmaceutical company that is focused on developing and commercializing innovative therapies for the treatment of cancer and other diseases. The company is headquartered in the United States, and it has a proven track record of developing effective and safe therapies that have the potential to transform the lives of patients around the world.
The company's mission is to develop first-in-class or best-in-class therapies that address the unmet medical needs of patients. Renovorx's approach is based on cutting-edge science that utilizes novel, targeted therapies that have the potential to be more effective and less toxic than traditional chemotherapy and radiation treatments.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com